// App-Quantinova.ai

: BST-236 - A NOVEL SAFE AND EFFECTIVE FIRST-LINE THERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD CHEMOTHERAPY. SUMMARY OF CLINICAL RESULTS TO DATE

Researchers

Presenter

  • Tsila Zuckerman

Principal Investigators

  • Jessica K Altman

  • Ron Ram

  • Micah Burch

  • Ofir Wolach

  • Itay Levi

  • Anna Gourevitch

  • Liat Flaishon

  • Shoshi Tessler

  • Stela Gengrinovitch

  • Ruth Ben Yakar

  • Jacob M Rowe

Medical Centers

  • Rambam Health Care Campus, Haifa, Israel

  • Rush University Medical Center, Chicago, Illinois, United States

  • Assuta Medical Center, Tel Aviv, Israel

  • Baylor Scott & White Research Institute,Dallas TX,United States

  • Rabin Medical Center, Petach Tikvah, Israel

  • Soroka University Medical Center, Beer Sheva, Israel

  • BioSight Ltd.,Lod,Israel

  • Shaare Zedek Medical Center, Jerusalem, Israel

Locations

  • Israel

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved